Gilead Sciences News
The Best Healthcare Bet
Unsustainably high dividends, valuations, and struggling industries dominate today's list.
Gilead was a leading decliner within the drugs industry, falling $1.20 (-2.3%) to $51.03 on average volume
Huge Upside on Pipeline Strength
Gilead's sofosbuvir will get priority review, which brings it one step closer to upping the bar in hepatitis C treatment.
New approaches to HIV prevention.
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
Analysts shift stance on Gilead Sciences, Celgene, and DreamWorks Animation.